Journal article
Plasma neurofilament light chain and phosphorylated tau 181 in neurodegenerative and psychiatric disorders: moving closer towards a simple diagnostic test like a 'C‐reactive protein' for the brain?
Dhamidhu Eratne, Alexander Santillo, Qiao‐Xin Li, Matthew Kang, Michael Keem, Courtney Lewis, Samantha M Loi, Mark Walterfang, Oskar Hansson, Shorena Janelidze, Nawaf Yassi, Rosie Watson, Samuel F Berkovic, Colin L Masters, Steven Collins, Dennis Velakoulis
Alzheimer's & Dementia | Wiley | Published : 2021
DOI: 10.1002/alz.058647
Abstract
AbstractBackgroundAccurate, timely diagnosis of neurodegenerative disorders, in particular distinguishing primary psychiatric from neurological disorders and in younger people, can be challenging. There is a need for biomarkers to reduce the diagnostic odyssey and improve outcomes. Neurofilament light (NfL) has shown promise as a diagnostic biomarker in a wide range of disorders. Our Markers in Neuropsychiatric Disorders (MiND) Study builds on our pilot (Eratne et al, ANZJP, 2020), to explore the diagnostic and broader utility of plasma and cerebrospinal fluid (CSF) NfL and other novel markers such as phosphorylated tau 181 (p‐tau181), in a broad range of psychiatric and neurodegenerative/ne..
View full abstract